Ripple Neuro

Ripple Neuro operates in the neuroscience research tools and neural medical-device segment, serving researchers working with neural signals, stimulation, and neuroprosthetic applications. Its product portfolio spans the Grapevine modular electrophysiology system, processors, front ends for different electrode types and research models, I/O modules, and adapters. That combination suggests a systems approach: researchers can pair acquisition and stimulation hardware with interfaces suited to their experimental setup, rather than relying on a single-purpose device. The company also describes implantable technologies such as MIRA and SARA, extending its work toward prosthetic control and sensory feedback. Its researcher-led expertise across neuroscience, electrical engineering, software, and medical-device development is a differentiator indicated by its stated capabilities. Ripple Neuro is a private, established specialist, founded in 2004, with an employee range of 11–50 and a focus on research and potential clinical applications.

Ripple Neuro’s trajectory is characterized by a long operating history and a broadening portfolio of neural interface tools, rather than a documented sequence of venture rounds or rapid scale-up milestones. Founded in 2004, the company has developed the Grapevine modular electrophysiology platform and associated processors, front ends, I/O modules, and adapters. Its work also includes implantable concepts such as the MIRA 32-electrode array and SARA 64-electrode array, alongside flexible electrodes and a blink-prosthesis prototype. These products point to an expansion from research instrumentation toward applications involving prosthetic control, sensory feedback, and neuromodulation. The company reports $35 million in SBIR/STTR grants and contracts; this figure should not be interpreted as disclosed equity financing. Andrew Wilder has been CEO since December 2018.